Merck and GlaxoSmithKline Collaborate on Pazopanib - - BioPharm International

ADVERTISEMENT

Merck and GlaxoSmithKline Collaborate on Pazopanib



Merck & Co. announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s (GSK) orally administered kinase inhibitor, pazopanib, for the treatment of advanced renal-cell carcinoma.

Merck and GSK entered a collaboration to study MK-3475 with pazopanib and other agents in the GSK portfolio. This Phase I and Phase II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment naïve patients with advanced renal-cell carcinoma.

Source: Merck & Co.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Author Guidelines

Click here